...
首页> 外文期刊>International medical journal: IMJ >Why Do the New Drugs Based on the Glutamate Hypothesis Seem to be Difficult to Exert Clinical Efficacy Solely in Schizophrenia?
【24h】

Why Do the New Drugs Based on the Glutamate Hypothesis Seem to be Difficult to Exert Clinical Efficacy Solely in Schizophrenia?

机译:为什么基于谷氨酸盐假说的新药似乎很难完全发挥精神分裂症的临床功效?

获取原文
获取原文并翻译 | 示例
           

摘要

Background: There have been active attempts of creating new drugs based on the glutamate hypothesis in schizophrenia. However, none of these drugs seems to have exerted clinical efficacy solely.Method: The stability of the corticostriatal loop is examined in schizophrenia by using the recent computational simulation studies on control of working memory.Result: The stability of the loop depends on the feedback gain (K value). If the K value exceeds 1, the loop becomes catastrophic.Conclusion: Once the prefrontal dopamine decreases markedly, the K value exceeds 1 and the corticostriatal loop becomes unstable, making it difficult to maintain the stability of the loop with glutamatergic neurotransmission. This is probably one of the reasons why the new drugs based on the glutamate hypothesis seem to be difficult to exert clinical efficacy solely.
机译:背景:在精神分裂症中,人们已经根据谷氨酸假说积极尝试开发新药。然而,这些药物似乎都不能完全发挥临床功效。方法:通过最近对工作记忆控制的计算机模拟研究,对精神分裂症患者的皮质口环的稳定性进行了研究。结果:环的稳定性取决于反馈增益(K值)。如果K值超过1,则该环路将成为灾难性的。结论:一旦额叶前多巴胺明显降低,K值将超过1,皮质皮质环变得不稳定,从而难以通过谷氨酸能神经传递来维持环路的稳定性。这可能是基于谷氨酸假说的新药似乎难以单独发挥临床功效的原因之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号